CoChat
Sign Up
Cited by 344

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders

Ingelsson, Martin·2016·Frontiers in Neuroscience
DOI 10.3389/fnins.2016.00408PMC PMC5011129
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2016.00408

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. Aasly, 2014, Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers, Front. Aging Neurosci., 6, 10.3389/fnagi.2014.00248 · DOI
  2. Appel-Cresswell, 2013, Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease, Mov. Disord., 28, 811, 10.1002/mds.25421 · DOI
  3. Bae, 2012, Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission, J. Neurosci., 32, 13454, 10.1523/JNEUROSCI.1292-12.2012 · DOI · Paper page
  4. Bellingham, 2012, Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?, Front. Physiol., 3, 10.3389/fphys.2012.00124 · DOI · Paper page
  5. Bieschke, 2010, EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl. Acad. Sci. U.S.A., 107, 7710, 10.1073/pnas.0910723107 · DOI
  6. Bliederhaeuser, 2016, Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes, Acta Neuropathol., 131, 379, 10.1007/s00401-015-1504-2 · DOI
  7. Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol. Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 · DOI · Paper page
  8. Braak, 2006, Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology, Neurosci. Lett., 396, 67, 10.1016/j.neulet.2005.11.012 · DOI · Paper page
  9. Brännström, 2014, A generic method for design of oligomer-specific antibodies, PLoS ONE, 9, e90857, 10.1371/journal.pone.0090857 · DOI
  10. Burré, 2015, The synaptic function of alpha-synuclein, J. Parkinsons. Dis., 5, 699, 10.3233/JPD-150642 · DOI
  11. Burré, 2010, Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro, Science, 329, 1663, 10.1126/science.1195227 · DOI
  12. Burré, 2013, Properties of native brain alpha-synuclein, Nature, 498, E4, 10.1038/nature12125 · DOI
  13. Cappai, 2005, Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway, FASEB J., 19, 1377, 10.1096/fj.04-3437fje · DOI
  14. Chandra, 2003, A broken alpha -helix in folded alpha -synuclein, J. Biol. Chem., 278, 15313, 10.1074/jbc.M213128200 · DOI
  15. Chartier-Harlin, 2004, Alpha-synuclein locus duplication as a cause of familial Parkinson's disease, Lancet, 364, 1167, 10.1016/S0140-6736(04)17103-1 · DOI · Paper page
  16. Chen, 2013, Alpha-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity, J. Biol. Chem., 288, 7438, 10.1074/jbc.M112.439497 · DOI
  17. Chinta, 2010, Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo, Neurosci. Lett., 486, 235, 10.1016/j.neulet.2010.09.061 · DOI
  18. Choi, 2013, Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking, Proc. Natl. Acad. Sci. U.S.A., 110, 4087, 10.1073/pnas.1218424110 · DOI
  19. Colla, 2012a, Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo, J. Neurosci., 32, 3306, 10.1523/JNEUROSCI.5367-11.2012 · DOI
  20. Colla, 2012b, Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo, J. Neurosci., 32, 3301, 10.1523/JNEUROSCI.5368-11.2012 · DOI
  21. Conway, 1998, Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease, Nat. Med., 4, 1318, 10.1038/3311 · DOI
  22. Conway, 2000, Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations limked to early-onset Parkinson's disease: Implications for pathogenesis and therapy, Proc. Natl. Acad. Sci. U.S.A., 97, 571, 10.1073/pnas.97.2.571 · DOI
  23. Danzer, 2007, Different species of alpha-synuclein oligomers induce calcium influx and seeding, J. Neurosci., 27, 9220, 10.1523/JNEUROSCI.2617-07.2007 · DOI · Paper page
  24. Danzer, 2012, Exosomal cell-to-cell transmission of alpha synuclein oligomers, Mol. Neurodegener., 7, 42, 10.1186/1750-1326-7-42 · DOI
  25. Danzer, 2009, Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology, J. Neurochem., 111, 192, 10.1111/j.1471-4159.2009.06324.x · DOI · Paper page
  26. Diógenes, 2012, Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation, J. Neurosci., 32, 11750, 10.1523/JNEUROSCI.0234-12.2012 · DOI
  27. Ehrnhoefer, 2008, EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers, Nat. Struct. Mol. Biol., 15, 558, 10.1038/nsmb.1437 · DOI
  28. Esterbauer, 1991, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, Free Radic. Biol. Med., 11, 81, 10.1016/0891-5849(91)90192-6 · DOI · Paper page
  29. Fagerqvist, 2013a, Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation, J. Neurochem., 126, 131, 10.1111/jnc.12175 · DOI
  30. Fagerqvist, 2013b, Off-pathway alpha-synuclein oligomers seem to alter alpha-synuclein turnover in a cell model but lack seeding capability in vivo, Amyloid, 20, 233, 10.3109/13506129.2013.835726 · DOI
  31. Fauvet, 2012, Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer, J. Biol. Chem, 287, 15345, 10.1074/jbc.M111.318949 · DOI
  32. Games, 2014, Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models, J. Neurosci., 34, 9441, 10.1523/JNEUROSCI.5314-13.2014 · DOI
  33. Hansson, 2014, Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease, Alzheimers Res. Ther., 6, 25, 10.1186/alzrt255 · DOI
  34. Hong, 2008, Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein, J. Mol. Biol., 383, 214, 10.1016/j.jmb.2008.08.039 · DOI
  35. Hong, 2009, Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?, Biochim. Biophys. Acta, 1794, 282, 10.1016/j.bbapap.2008.09.026 · DOI
  36. Houlden, 2012, The genetics and neuropathology of Parkinson's disease, Acta Neuropathol., 124, 325, 10.1007/s00401-012-1013-5 · DOI
  37. Jakes, 1994, Identification of two distinct synucleins from human brain, FEBS Lett., 345, 27, 10.1016/0014-5793(94)00395-5 · DOI
  38. Karpinar, 2009, Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models, EMBO J., 28, 3256, 10.1038/emboj.2009.257 · DOI · Paper page
  39. Kaufmann, 2016, Intracellular soluble alpha-synuclein oligomers reduce pyramidal cell excitability, J. Physiol., 594, 2751, 10.1113/JP271968 · DOI
  40. Kim, 1997, Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil, Mol. Cells, 7, 78, 10.1016/S1016-8478(23)13265-1 · DOI
  41. Klucken, 2012, Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway, Autophagy, 8, 754, 10.4161/auto.19371 · DOI
  42. Kramer, 2007, Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies, J. Neurosci., 27, 1405, 10.1523/JNEUROSCI.4564-06.2007 · DOI · Paper page
  43. Krüger, 1998, Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease, Nat. Genet., 18, 106, 10.1038/ng0298-106 · DOI · Paper page
  44. Lashuel, 2002, Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils, J. Mol. Biol., 322, 1089, 10.1016/S0022-2836(02)00735-0 · DOI
  45. Lesage, 2013, G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome, Ann. Neurol., 73, 459, 10.1002/ana.23894 · DOI
  46. Lindström, 2014, Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice, Neurobiol. Dis., 69, 134, 10.1016/j.nbd.2014.05.009 · DOI
  47. Mandler, 2014, Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials, Acta Neuropathol., 127, 861, 10.1007/s00401-014-1256-4 · DOI
  48. Masliah, 2005, Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease, Neuron, 46, 857, 10.1016/j.neuron.2005.05.010 · DOI · Paper page
  49. Masliah, 2011, Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease, PLoS ONE, 6, e19338, 10.1371/journal.pone.0019338 · DOI
  50. Mendez, 2008, Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years, Nat. Med., 14, 507, 10.1038/nm1752 · DOI
  51. Nässträm, 2011, The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties, Free Radic. Biol. Med., 50, 428, 10.1016/j.freeradbiomed.2010.11.027 · DOI
  52. Näsström, 2009, The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers, Biochem. Biophys. Res. Commun., 378, 872, 10.1016/j.bbrc.2008.12.005 · DOI
  53. Outeiro, 2008, Formation of toxic oligomeric alpha-synuclein species in living cells, PLoS ONE, 3, e1867, 10.1371/annotation/9282f173-df82-4b70-9120-b4e62b3dacb1 · DOI · Paper page
  54. Paleologou, 2009, Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies, Brain, 132, 1093, 10.1093/brain/awn349 · DOI
  55. Parihar, 2009, Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells, Int. J. Biochem. Cell Biol., 41, 2015, 10.1016/j.biocel.2009.05.008 · DOI
  56. Park, 2011, Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease, J. Clin. Neurol., 7, 215, 10.3988/jcn.2011.7.4.215 · DOI
  57. Parnetti, 2014, Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease, Mov. Disord., 29, 1019, 10.1002/mds.25772 · DOI
  58. Proukakis, 2013, A novel alpha-synuclein missense mutation in Parkinson disease, Neurology, 80, 1062, 10.1212/WNL.0b013e31828727ba · DOI
  59. Qin, 2007, Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation, J. Biol. Chem., 282, 5862, 10.1074/jbc.M608126200 · DOI
  60. Rockenstein, 2014, Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo, Brain, 137, 1496, 10.1093/brain/awu057 · DOI
  61. Sanchez-Guajardo, 2013, Alpha-synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model, J. Neuropathol. Exp. Neurol., 72, 624, 10.1097/NEN.0b013e31829768d2 · DOI
  62. Shamoto-Nagai, 2007, In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity, J Neural. Transm. (Vienna), 114, 1559, 10.1007/s00702-007-0789-2 · DOI
  63. Sharon, 2003, The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease, Neuron, 37, 583, 10.1016/S0896-6273(03)00024-2 · DOI
  64. Sierks, 2011, CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease, Integr. Biol. (Camb)., 3, 1188, 10.1039/c1ib00018g · DOI
  65. Singleton, 2003, α-Synuclein locus triplication causes Parkinson's disease, Science, 302, 841, 10.1126/science.1090278 · DOI · Paper page
  66. Spencer, 2016, α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease, Ann. Clin. Translat. Neurol., 10.1002/acn3.321 · DOI
  67. Theillet, 2016, Structural disorder of monomeric alpha-synuclein persists in mammalian cells, Nature, 530, 45, 10.1038/nature16531 · DOI
  68. Tokuda, 2006, Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease, Biochem. Biophys. Res. Commun., 349, 162, 10.1016/j.bbrc.2006.08.024 · DOI · Paper page
  69. Tosatto, 2015, Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants, Sci. Rep., 5, 16696, 10.1038/srep16696 · DOI
  70. Unterberger, 2014, Detection of disease-associated alpha-synuclein in the cerebrospinal fluid: a feasibility study, Clin. Neuropathol., 33, 329, 10.5414/NP300796 · DOI
  71. Uversky, 2002, Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro, FEBS Lett., 517, 239, 10.1016/S0014-5793(02)02638-8 · DOI
  72. Volles, 2002, Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism, Biochemistry, 41, 4595, 10.1021/bi0121353 · DOI
  73. Volles, 2001, Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease, Biochemistry, 40, 7812, 10.1021/bi0102398 · DOI
  74. Weinreb, 1996, NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry, 35, 13709, 10.1021/bi961799n · DOI
  75. Wilms, 2009, Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils, Int. J. Immunopathol. Pharmacol., 22, 897, 10.1177/039463200902200405 · DOI
  76. Winner, 2011, In vivo demonstration that alpha-synuclein oligomers are toxic, Proc. Natl. Acad. Sci. U.S.A., 108, 4194, 10.1073/pnas.1100976108 · DOI · Paper page
  77. Zaltieri, 2015, Alpha-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons, J. Cell Sci., 128, 2231, 10.1242/jcs.157867 · DOI
  78. Zarranz, 2004, The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia, Ann. Neurol., 55, 164, 10.1002/ana.10795 · DOI · Paper page
  79. Zhou, 2009, At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation, J. Mol. Biol., 388, 597, 10.1016/j.jmb.2009.03.053 · DOI
  80. Zhou, 2010, Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions, Biochim. Biophys. Acta, 1802, 322, 10.1016/j.bbadis.2009.12.004 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ingelsson, M.
Venue
Frontiers in Neuroscience
Publisher
Frontiers Media SA
Published
2016-09-05
Volume
10
ISSN
1662-453X
DOI
10.3389/fnins.2016.00408
PMC
PMC5011129
Cited by
344
References
12

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review